The Value & Innovation Forum is a collaboration of the National Forum for Heart Disease & Stroke Prevention and Patient Advocate Foundation, both 501(c)(3) nonprofit organizations. Briefing topics are selected by the Value & Innovation Forum Steering Committee which includes representatives of the Alliance of Community Health Plans and Association of Black Cardiologists, in addition to the National Forum and Patient Advocate Foundation. Briefings are made possible by funding from Amgen in accordance with the National Forum’s Policy on Corporate and Foundation Support and Relationships. This policy ensures transparency and integrity in the National Forum’s dealings with sponsors.
RESOURCES:
SPEAKERS:
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, Gerald S. Berenson Endowed Chair in Preventive Cardiology, Professor of Medicine @Tulane University School of Medicine
Richard Towne, PharmD, Clinical Informatics Manager @Antidote
RESOURCES:
Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement – December 2021
Increasing Diversity in Clinical Trials: Overcoming Critical Barriers – November 2021
Keith C. Ferdinand, MD Excerpt
Webinar Recording / Webinar Summary (To Be Added Soon!)
SPEAKERS:
Moderator: John Clymer, Executive Director, National Forum
Juliana Reed, President of Biosimilars Forum
Zeid El-Kilani, Economist, US Department of Health and Human Services
Chad Pettit, Executive Director Marketing, Global Biosimilars Commercial Lead, Amgen
Robert Lash, Chief Medical Officer, Endocrine Society
RESOURCES:
Biosimilars Forum report October 2021
Health Affairs Article June 2021
Webinar Recording | Webinar Summary
Alan Balch, PhD, Chief Executive Officer, Patient Advocate Foundation & National Patient Advocate Foundation
Julia Resnick, Senior Program Manager for Strategic Initiatives, American Hospital Association
Katlyn Sollenberger, Site Specialist, The Rinehart Clinic, Wheeler, OR
Proposed New Codes for SDOH Z Codes
Kaiser Permanente Infographic on Z Codes
American Hospital Association ICD-10-CM Coding for Social Determinants of Health
Webinar Recording | Webinar Summary
Shonta Chambers, MSW
Executive Vice President, Health Equity & Community Engagement
Principal Investigator, SelfMade Health Network
Patient Advocate Foundation
Barbara Hutchinson, MD PhD, FACC
President, Chesapeake Cardiac Care
Past President, Association of Black Cardiologists
Connie Hwang, MD, MPH
Chief Medical Officer, Director of Clinical Innovation
Alliance of Community Health Plans
Patient Advocate Foundation Telehealth Tip Sheet
ACHP Fact Sheet – The Promise of Telehealth (April 2021)
Regional Payers Outline Challenges, Successes of Telehealth Implementation (AJMC Feb 2021)
Webinar Recording | Webinar Summary
Traditional utilization management has become burdensome for physicians and patients. This 1-hour briefing brings forward innovative real-world examples to navigate utilization management.
Kate Berry, Senior Vice President of Clinical Innovation, America’s Health Plans
Jay Scott, Director, Managed Care, Minnesota Oncology
Robin T. Zon, MD, FACP, FASCO Chair, ASCO Pathways Task Force
President, Finance & Quality Chair, Michiana Hematology-Oncology, PC
Alan Balch, PhD, CEO, Patient Advocate Foundation, National Patient Advocate Foundation
American Society of Clinical Oncology (ASCO) Policy Statement On the Impact of Utilization Management Policies for Cancer Drug Therapies
America’s Health Insurance Plans (AHIP) Fast Prior Authorization Technology Highway (Fast PATH)
Journal Article: Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative’s Prior Authorization Learning Collaborative
Webinar Recording
Welcome & Introduction (0:01)
Tricia Neuman (4:25)
Judith Stein (17:52)
Michael Bagel (30:00)
Discussion (40:00)
Webinar Summary | Slides | Speaker Bios
Increased focus on public options like “Medicare for All” along with historic increases in Medicare Advantage enrollment make this the right time for patient groups to learn more about different approaches and related policy issues!
Medicare Advantage vs. Traditional Medicare Decision Tree
Medicare Advantage – Serving a Diverse, Rapidly Growing Population
Medicare Advantage – Choice of America’s Seniors
Medicare Advantage – Savings for Seniors and the Nation
Medicare Advantage – Higher Standards, Quality, Coverage
Webinar Recording | Webinar Summary | Slides
Biosimilars continue to be a controversial subject long after Congress created a pathway for their approval. The Value & Innovation Forum prides itself on creating forums that present all sides of an issue as well as new and interesting angles beyond the hotly debated. This session provides an interesting discussion about the “rebate wall” controversy in biosimilars, a patient perspective, and where the FDA is headed next.
John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Christine Simmon, JD, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Madelaine Feldman, MD, Practicing Rheumatologist, Founding Member & Past President, Rheumatology Alliance of Louisiana
John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Bio
Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Bio
Christine Simmon, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Bio
Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Bio
Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Bio
Madelaine Feldman, MD, Practicing Rheumatologist, President, Coalition of State Rheumatology Organizations
Bio
Formulary Construction in America: ‘Perfectly Legal’ and ‘Perfectly Wrong
Op-Ed: Debate Over Pharmacy Benefit Managers a Matter of Price vs. Cost
Washington Must Change the System That Encourages High Drug Prices
Lessons for the United States on Europe’s Biosimilar Experience
FDA Biosimilars for access to educational materials and information about biosimilar and interchangeable products.
Drugs@FDA for information on all FDA approved drug products, including labeling and review information.
FDA Advisory Committees for drug advisory committee meetings and materials related to biosimilars
FDA Purple Book a database of Licensed Biological Products for information on biological products, including if products are biosimilar to a reference product.